SpaceX Going Public Is Not a Reason to Abandon Rocket Lab

Rocket Lab reported Q1 revenue up 63.5% YoY to $200.3M, with GAAP gross margin of 38.2% and backlog up 20.2% sequentially to $2.2B, supported by 31 new Electron/HASTE contracts and additional Neutron awards. The company expects Q2 revenue of $225M–$240M (+16% sequentially at the midpoint) and is targeting a planned $8B acquisition of Iridium to expand into satellite operations and communications services. Key risks include a Neutron launch target pushed to Q4 2026 after a development setback and continued losses (Q1 net loss of $45M; adjusted EBITDA loss of $20M–$26M in Q2), making the outlook promising but execution-dependent.

Analysis

RKLB is the clearest short-term beneficiary of the current “space re-rating” trade, but the mechanism is multiple expansion more than fundamentals: public-market attention can lift EV/revenue before operating leverage is proven. The more interesting secondary winner is IRDM, because the proposed transaction turns it from a niche satcom operator into an embedded optionality asset; if the market starts pricing deal probability, IRDM should outperform on spread compression even before closing.

The market should not confuse headline revenue growth with de-risked equity value. RKLB’s biggest swing factor is not launch cadence; it is whether Neutron slips again and whether the company can fund an $8B strategic move without pushing dilution or leverage into a still-loss-making model. That creates a fragile setup over the next 1-3 months: a strong tape can carry the name, but any financing detail, integration concern, or another schedule push can quickly compress the premium. KTOS gets a modest read-through from hypersonic testing demand, but the real beneficiary is the broader defense-launch funding bucket, not any single prime.

Contrarian view: consensus is treating this as a SpaceX proxy, but SpaceX’s public-market halo may actually cap RKLB’s valuation by forcing a harder comparison on execution, scale, and capital efficiency. Over 6-18 months, RKLB’s move from launch-only to communications operator could be strategically powerful but economically more capital intensive, which is not automatically bullish for per-share value. What would falsify the bullish case is another Neutron delay, weak backlog conversion, or any sign the IRDM deal needs punitive equity issuance.

Key Decisions for Investors

• Long IRDM / short RKLB as a deal-spread expression only if the acquisition terms remain actionable; target a 2-4 month horizon and exit if financing language shifts toward heavy dilution.
• Buy RKLB on pullbacks only, not into strength; treat it as a momentum trade with a tight risk line around any renewed Neutron-delay headline or Q2 margin miss.
• Use KTOS as a lower-beta way to express defense-launch spillover: long KTOS on evidence of sustained hypersonic program funding, but size modestly because the read-through is second order.
• Set a watch trigger on RKLB EBITDA and cash burn in the next print; if losses fail to narrow while backlog keeps rising, fade the multiple expansion.
• If the market prices IRDM as a takeout, consider taking profits into spread tightening rather than holding for close risk; the upside is front-loaded, the break risk is binary.